11 leading stroke scientists receive top honors for career and research contributions
( NewMediaWire) - February 04, 2025 - LOS ANGELES, Feb. 4, 2025 – Eleven scientists will be recognized for their individual exceptional professional achievements and contributions to stroke care and research during the American Stroke Association's International Stroke Conference 2025. The meeting will be held in Los Angeles, Feb. 4-7, and is a world premier meeting for researchers and clinicians dedicated to the science of stroke and brain health.
The awardees include four groundbreaking scientists who have devoted their careers to stroke research and six other scientists who will be recognized for their new research findings, which will be presented during the meeting.
The 2025 honorees are:
Virginia J. Howard, Ph.D., FAHA, University of Alabama at Birmingham, Birmingham, Alabama, will receive the Edgar J. Kenton III Lecture Award.
Yongjun Wang, M.D., Beijing Tiantan Hospital, Capital Medical University, Beijing, China, will be honored with the William M. Feinberg Award for Excellence in Clinical Stroke.
Heather J. Fullerton, M.D., University of California San Francisco, San Francisco, California, will receive the Ralph L. Sacco Outstanding Stroke Research Mentor Award.
Miguel A. Perez-Pinzon, Ph.D., FAHA, University of Miami Miller School of Medicine, Miami, Florida, will receive the Thomas Willis Lecture Award.
Jean-Claude Baron, M.D., Sc.D., INSERM, University Paris Cité in France, will receive the David G. Sherman Lecture Award.
Shufan Huo, M.D., Ph.D., Yale University in New Haven, Connecticut, will receive the Mordecai Y.T. Globus New Investigator Award.
Heyu Ni, M.D., Ph.D., University of Toronto, Ontario, will receive the Stroke Basic Science Award.
Mohamed Elfil, M.D., University of Miami/Jackson Health System, Florida will receive this year's Robert G. Siekert New Investigator Award in Stroke.
Santosh Murthy, M.D., M.P.H., Weill Cornell Medical College and New York-Presbyterian Hospital/Weill Cornell in New York will receive the Stroke Care in Emergency Medicine Award.
Cyprien A. Rivier, M.D. M.Sc., Yale School of Medicine, New Haven, Connecticut, will receive the Vascular Cognitive Impairment Award.
Mei Zhen Huang, Ph.D., University of Maryland School of Medicine in Baltimore, Maryland, will be awarded the Stroke Rehabilitation Award.
Virginia J. Howard, Ph.D., FAHA, the Edgar J. Kenton III Lecture Award recipient, is a Distinguished Professor of Epidemiology at the School of Public Health, University of Alabama at Birmingham in Birmingham, Alabama. She is a stroke epidemiologist with more than 30 years of experience in multicenter, multidisciplinary clinical trials and longitudinal cohort studies with a focus on stroke, stroke risk factors, cognitive functioning and health disparities. The Edgar J. Kenton III Lecture Award recognizes lifetime contributions to the investigation, management, mentorship and community service in the field of racial and ethnic stroke disparities or related disciplines. The award honors the late Edgar J. Kenton III, a former chair of the American Heart Association's Stroke Council and an eminent Black vascular neurologist passionate about bridging race/ethnic disparities in stroke.
Howard will present the Edgar J. Kenton III lecture in the preconference symposium HEADS-UP, 'Recruiting and Retaining Diverse and Underrepresented Participants in Studies of Stroke and Brain Health: It Takes a Village, $$$, Planning and Long-Term Commitment,' at 10:18 a.m. PT, Tuesday, Feb. 4.
Yongjun Wang, M.D., the William M. Feinberg Award for Excellence in Clinical Stroke awardee, is the president of Beijing Tiantan Hospital, Capital Medical University, and is also the president of the Chinese Stroke Association. Wang has worked on secondary prevention strategies and reperfusion therapy for ischemic stroke. The Feinberg Award is named for the late William M. Feinberg, a prominent stroke clinician-researcher and American Heart Association volunteer who contributed to a more comprehensive understanding of the causes of stroke. The award recognizes significant contributions to the investigation and management of clinical research in stroke.
Wang's lecture, 'Thirty Years of Treatment for Acute Ischemic Cerebrovascular Events: The Power of Evidence,' will be presented at 11:22 a.m. PT, Wednesday, Feb. 5.
Heather J. Fullerton, M.D., the recipient of the Ralph L. Sacco Outstanding Stroke Research Mentor Award, is a professor of neurology and pediatrics at the University of California San Francisco and president of the International Pediatric Stroke Organization. Her research investigates the causes of stroke in children, particularly the role of infection, and she is currently leading a clinical trial for the treatment of a disease of inflamed brain blood vessels in children. The late Ralph L. Sacco was the first neurologist to serve as the volunteer president of the American Heart Association. The Sacco Award honors outstanding achievements in mentoring future generations of stroke researchers in the field of cerebrovascular disease.
Fullerton will present her lecture, 'Mentoring to Propel Progress in Pediatric Stroke,' at 11:02 a.m. PT, Thursday, Feb. 6.
Miguel A. Perez-Pinzon, Ph.D., FAHA, the recipient of the Thomas Willis Lecture Award, is the professor and vice-chair for discovery science of neurology at the University of Miami Miller School of Medicine in Miami, Florida. Perez-Pinzon's research expertise is cerebral ischemia, which results from cardiac arrest or stroke. His research focuses on the areas of synaptic, cognitive, vascular and mitochondrial dysfunction that ensue following an ischemic stroke. The Willis Award is named after the late Thomas Willis, a pioneer physician who provided the first detailed descriptions of the brain stem, cerebellum, ventricles and hypotheses on their function. The award recognizes contributions to investigating and managing stroke as it relates to basic science.
Perez-Pinzon's lecture, ' Nature's Blueprint for Ischemic Tolerance: Pre- and Post-Conditioning Strategies,' will be presented at 11:17 a.m. PT, Thursday, Feb. 6.
Jean-Claude Baron, M.D., Sc.D., the recipient of the David G. Sherman Lecture Award, is an active clinical neurologist and director of research at INSERM, University Paris Cité in France, and previously professor of stroke medicine at Cambridge University, United Kingdom. His research focuses on understanding the mechanisms underlying ischemic stroke. Using imaging, he looks at how treatment can rescue at-risk brain tissue and how brain tissue recovers its functions after a stroke. Along with his clinical research, Jean-Claude Baron conducts imaging studies using animal models that mimic human stroke. The Sherman Award honors the late David G. Sherman, a prominent stroke physician and an internationally recognized leader and researcher in stroke prevention and treatment. The award recognizes lifetime contributions to the investigation, management, mentorship and community service in the stroke field.
Baron will present his lecture, 'Fifty Years of Deciphering the Pathophysiology of Stroke ' at 11:02 a.m. PT, Friday, Feb. 7.
Shufan Huo, M.D., Ph.D., the Mordecai Y.T. Globus New Investigator Award in Stroke awardee, is a postdoctoral fellow at the Falcone Lab in the Department of Neurology at Yale University in New Haven, Connecticut. The award is named after the late Mordecai T. Globus, a renowned cerebrovascular researcher, and is given to a researcher in training. Huo's award-winning presentation, Abstract 15, 'Integrated Genomic and Proteomic Drug Target Discovery for Ischemic Stroke,' will be presented at 7:30 a.m. PT, Wednesday, Feb. 5.
Heyu Ni, M.D., Ph.D., the Stroke Basic Science Award recipient, is a professor in the laboratory of medicine and pathobiology, medicine, and physiology departments at the University of Toronto. Ni is also a senior scientist at the Canadian Blood Services Centre for Innovation and Keenan Research Centre of Unity Health Toronto in Canada. The Stroke Basic Science Award recognizes outstanding laboratory-based basic or translational science. Ni's presentation, Abstract 89, 'A First-in-Class Humanized Antibody Fragment Targeting Platelet Glycoprotein Ibα: A Comprehensive Preclinical Study of CA1001 for the Treatment of Acute Ischemic Stroke,' will be presented at 7:30 a.m. PT, Wednesday, Feb. 5.
Mohamed Elfil, M.D., the recipient of the Robert G. Siekert New Investigator Award in Stroke, is a vascular neurology fellow at the University of Miami/Jackson Health System. The Siekert New Investigator Award in Stroke recognizes the late Robert G. Siekert, founding chairman of the American Heart Association's International Conference on Stroke and Cerebral Circulation, now known as the International Stroke Conference. The award encourages new investigators to undertake or continue stroke-related research. Elfil's award-winning presentation, Abstract 2, ' Endovascular Thrombectomy Plus Intravenous Thrombolysis Versus Endovascular Thrombectomy Alone in Patients with Large Core Infarct,' will be presented at 7:30 a.m. PT, Wednesday, Feb. 5.
Santosh Murthy, M.D., M.P.H., the Stroke Care in Emergency Medicine Award recipient, is an associate professor of Neurology at Weill Cornell Medical College and is also the associate chief of the Division of Neurocritical Care at New York-Presbyterian Hospital/Weill Cornell in New York. The Stroke Care in Emergency Medicine Award encourages investigators to undertake or continue research in the emergent phase of acute stroke treatment and submit an abstract to the International Stroke Conference. Murthy's winning presentation, Abstract 44, 'Minimally Invasive Surgery is Associated with Improved Outcomes Compared to Open Craniotomy with Clot Evacuation after Spontaneous Intracerebral Hemorrhage in the AHA Get With The Guidelines Registry,' will be presented at 2:12 p.m. PT, Wednesday, Feb. 5.
Cyprien A. Rivier, M.D. M.Sc. is the Vascular Cognitive Impairment Award recipient. Rivier is an associate research scientist in neurology at the Yale School of Medicine in New Haven, Connecticut. The Vascular Cognitive Impairment Award encourages investigators to undertake or continue research or clinical work in the field of vascular cognitive impairment and submit an abstract to the International Stroke Conference. Rivier's award-winning presentation, Abstract 96, 'Integrated Genomic and Proteomic Profiling Support Cathepsin-B as a Drug Repurposing Target in Cerebral Small Vessel Disease , ' will be presented at 9:15 a.m. PT, Thursday, Feb. 6.
Mei Zhen Huang, Ph.D., the Stroke Rehabilitation Award recipient, was a postdoctoral fellow in the Department of Physical Therapy and Rehabilitation Science at the University of Maryland School of Medicine in Baltimore, Maryland. The Stroke Rehabilitation Award encourages investigators to undertake or continue research and/or clinical work in the field of stroke rehabilitation. Huang's winning presentation, Abstract 126, 'In-Bed Robot-Guided Ankle Sensory-Motor Rehabilitation in Early Subacute Stroke Survivors: A Preliminary Clinical Trial,' will be presented at 8:30 a.m. PT, Friday, Feb. 7
Statements and conclusions of studies that are presented at the American Heart Association's scientific meetings are solely those of the study authors and do not necessarily reflect the Association's policy or position. The Association makes no representation or guarantee as to their accuracy or reliability. Abstracts presented at the Association's scientific meetings are not peer-reviewed, rather, they are curated by independent review panels and are considered based on the potential to add to the diversity of scientific issues and views discussed at the meeting. The findings are considered preliminary until published as a full manuscript in a peer-reviewed scientific journal.
The Association receives funding primarily from individuals; foundations and corporations (including pharmaceutical, device manufacturers and other companies) also make donations and fund specific Association programs and events. The Association has strict policies to prevent these relationships from influencing the science content. Revenues from pharmaceutical and biotech companies, device manufacturers and health insurance providers and the Association's overall financial information are available here.
Additional Resources:
About the American Stroke Association
The American Stroke Association is devoted to saving people from stroke — the No. 2 cause of death in the world and a leading cause of serious disability. We team with millions of volunteers to fund innovative research, fight for stronger public health policies and provide lifesaving tools and information to prevent and treat stroke. The Dallas-based association officially launched in 1998 as a division of the American Heart Association. To learn more or to get involved, call 1-888-4STROKE or visit stroke.org Facebook, X.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
15-05-2025
- Medscape
Can Remote Monitoring Reduce Cancer Hospitalizations?
Remote symptom monitoring (RSM) using electronic patient-reported outcomes reduced hospitalizations by 19% at 3 months and 13% at 6 months in patients with cancer receiving systemic treatment. Implementation of RSM showed consistent benefits across diverse patient populations, including Black patients and those in rural or disadvantaged areas. METHODOLOGY: Previous randomized clinical trials demonstrated that RSM improved symptom burden, quality of life, and time of receiving treatment while reducing healthcare utilization. Despite such successful trials, implementation of electronic patient-reported outcomes in routine care has been limited, with few practices achieving successful integration. This new nonrandomized controlled trial with a hybrid type 2 implementation-effectiveness design included 1392 patients with cancer receiving RSM from 2021 to 2024, who were compared with 4557 historical controls from 2017 to 2021 at two Alabama-based academic institutions. Patients receiving chemotherapy, targeted therapy, or immunotherapy were enrolled in RSM, with a median age of 61 years, 67% women, 27% Black patients, and 19% from rural areas. Analysis focused on healthcare utilization outcomes at 3 and 6 months after RSM enrollment, including intensive care unit admissions, hospitalizations, and emergency department visits. Researchers used adjusted modified Poisson models to estimate relative risk and 95% CI of healthcare utilization, with additional stratified analyses by patient race, residence, neighborhood deprivation, insurance type, and comorbid conditions. TAKEAWAY: Hospitalizations among RSM patients were significantly lower than controls at both 3 months (relative risk [RR], 0.81; 95% CI, 0.73-0.91) and 6 months (RR, 0.87; 95% CI, 0.80-0.96). Emergency department visits showed no significant differences between groups at 3 months (RR, 1.02; 95% CI, 0.89-1.16) and 6 months (RR, 1.03; 95% CI, 0.92-1.15). Intensive care unit admissions demonstrated no significant differences between RSM and control populations at 3 months (RR, 0.82; 95% CI, 0.59-1.13) and 6 months (RR, 0.83; 95% CI, 0.65-1.06). According to the researchers, similar patterns in relative risk were observed across patient subgroups, including those stratified by race, rurality, and socioeconomic status. IN PRACTICE: 'In this nonrandomized controlled trial, RSM implementation was associated with reduced risk of hospitalizations for patients with cancer, supporting the need to expand implementation nationally…,' wrote the authors of the study. 'Findings were observed in a diverse patient population, supporting broad applicability and highlighting the potential for this [Enhancing Oncology Model-required] practice transformation activity to impact value in cancer care delivery.' SOURCE: The study was led by Gabrielle B. Rocque, MD, MSPH, University of Alabama at Birmingham. It was published online on May 13 in JAMA Network Open . LIMITATIONS: According to the authors, not all eligible patients participated in the RSM program due to incomplete roll-out and patient declination, potentially introducing selection bias. The study population included few Hispanic patients and other subpopulations who may have unique language and cultural needs. Additionally, the analysis was limited to two academic centers and may not fully represent experiences in community practice settings. The researchers noted that electronic medical record–based analyses were limited in capturing utilization outside the participating centers, and outcomes for patients who declined or had incomplete survey participation were not assessed. DISCLOSURES: The study was supported by grant No. IR01NR019058 from the National Institute of Nursing Research. Rocque disclosed receiving grants from Pfizer and Daiichi Sankyo and personal fees from Gilead and being employed by Atlas Oncology Partners, outside the submitted work. Additional disclosures are noted in the original article.
CNET
10-05-2025
- CNET
Stroke Awareness: These 4 Letters Can Help You Save Lives
The Centers for Disease Control and Prevention reports that every 40 seconds, someone in the US experiences a stroke. Every 3 minutes and 11 seconds, someone dies of a stroke. The American Stroke Association defines a stroke as a "brain attack" that happens when the flow of blood to the brain is blocked, causing brain cells to die and brain damage to occur. Fortunately, there is something we can do to help. Using the acronym "FAST," we can easily remember the warning signs of a stroke. The sooner a person is treated for a stroke, the better the outcome, which is why identifying that a stroke is happening can save lives. Read on to learn more about what FAST means. Signs of a stroke General signs of a stroke include: Numbness in the face, arm or leg, particularly on one side of your body Difficulty speaking or understanding others Sudden confusion and mental fogginess Sudden vision issues in one or both eyes Sudden dizziness, incoordination and trouble walking Sudden migraine headache Signs of a stroke tend to look the same in men and women but signs can be less intense in women and often are overlooked. In addition to the signs listed above, women may also feel the following symptoms before stroke: Fatigue Headaches Mind fogginess and memory issues Nausea and vomiting Remember FAST to help identify a stroke This is where the acronym FAST comes in. It's a helpful resource to help recognize if someone is having a stroke and what you should do. F: Face drooping One side of the face is drooping and unable to function as normal. A: Arm weakness One arm suddenly feels numb or weak and cannot be raised simultaneously with the other. S: Speech difficulty Someone is blurring their speech, speaking incoherently or unable to repeat phrases. T: Time to call 911 If you or someone is experiencing one or more of these symptoms, especially on one side of the body, call 911 immediately. Quick medical care is vital in preventing serious long-term harm or disability. Note that the acronym was "BEFAST" for balance problems, eyesight problems, face muscle drooping, arm numbness, speech difficulties and time to call for help. However, a 2024 randomized pilot trial found that people had higher retention and ability to recall stroke symptoms, either partially or fully, with FAST. Possible causes of a stroke While there are risk factors of stroke that can't be changed, like family history or gender, some are preventable. Below is a list of possible stroke risk factors that can be managed: Diabetes Drug use Excessive alcohol consumption Heart disease High blood pressure Obesity Smoking For more advice on managing heart health, here are nine tips to help lower your risk of heart disease and what to do if someone is experiencing a heart attack.
Business Wire
08-05-2025
- Business Wire
Cadrenal Therapeutics Reports First-Quarter 2025 Financial Results and Provides Corporate Update
PONTE VEDRA, Fla.--(BUSINESS WIRE)-- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing therapeutics for patients with cardiovascular disease, today reported its financial results for the first quarter ended March 31, 2025, and provided an update on the strategic focus of the company and clinical development of tecarfarin. 'In the first quarter of 2025, Cadrenal continued to build on the momentum we achieved during 2024,' said Quang X. Pham, Chairman & CEO. 'The appointment of James Ferguson, M.D., FACC, FAHA, as our Chief Medical Officer positions us for success in reviewing potential assets to add to our portfolio and designing and executing our clinical program for tecarfarin. The finalized Collaboration Agreement with Abbott validates the critical need in the market for a new anticoagulant for patients with left ventricular assist devices (LVADs). And our meeting with the FDA provided additional guidance in the design of a pivotal trial.' Highlights from the Quarter Ended March 31, 2025, and Other Recent Events: Leadership Advances In February 2025, Cadrenal appointed James J. Ferguson, M.D., FACC, FAHA, as Chief Medical Officer to lead the review of business development opportunities to expand the Company's pipeline and drive the late-stage clinical development of tecarfarin for conditions requiring chronic anticoagulation therapy. Regulatory Update In February 2025, Cadrenal met with the U.S. Food and Drug Administration (FDA) for a Type D meeting. The FDA provided additional guidance on the appropriate design for a Phase 3 tecarfarin trial and welcomed submission of a final study design for review. Collaboration Agreement with Abbott In March 2025, we announced a Collaboration Agreement with Abbott (NYSE: ABT) to support our pivotal TECarfarin Anticoagulation and Hemocompatibility with Left Ventricular Assist Devices (TECH-LVAD) trial. Under the agreement, Abbott will share insights from recent HeartMate 3™ clinical trials and will support Cadrenal with trial design, site identification, trial awareness, and HeartMate 3™ expertise. Operational Milestones During the quarter, Cadrenal successfully completed the technical transfer and manufacturing of its tecarfarin drug substance (API) from a CDMO site located in Asia to a CDMO site in the United States. This initiative was done to support the company's clinical and regulatory development strategy for tecarfarin and to improve supply chain security. Cadrenal also conducted strategic market opportunity research for multiple indications, including patients with left ventricular assist devices. This research indicates that tecarfarin is uniquely positioned to provide clinical value to patients in the rapidly growing LVAD market, which is projected to nearly double by 2032. This research also showed that tecarfarin has the potential to provide clinical benefit in additional high-need cardiovascular, renal, and mechanical heart valve indications, reinforcing tecarfarin's potential value proposition for patients. Participation in Key Investor, Medical, and Business Development Conferences Cadrenal was active during the first quarter in several significant conferences to build corporate visibility and underscore its commitment to advancing innovation in anticoagulation therapy. Investor interactions included participation at the 43 rd Annual J.P. Morgan Healthcare Conference in San Francisco, a Company presentation at the BIO CEO and Investor Conference in New York, and, after the close of the quarter, a Company presentation at the Centri Capital Conference at Nasdaq headquarters in New York. Shortly after the quarter's close, Cadrenal participated in the 18 th National Conference on Anticoagulation Therapy in Washington, D.C. Strategic Development Collaborations Cadrenal continues to explore opportunities to add to the Company's clinical pipeline and collaborate with potential development partners to advance the development of tecarfarin for patients with LVADs and for other indications requiring chronic anticoagulation. First Quarter 2025 Financial Highlights Research and development expenses for the quarter ended March 31, 2025, were $1.7 million compared to $0.6 million for the same period in 2024. General and administrative expenses for the quarter ended March 31, 2025, were $2.3 million compared to $1.1 million for the same period in 2024. Cadrenal reported a net loss of $3.8 million for the quarter ending March 31, 2025, compared to $1.7 million for the same period in 2024. On March 31, 2025, Cadrenal had cash and cash equivalents of $7.3 million, compared to $10.0 million as of December 31, 2024. The Company had approximately 1.9 million shares of common stock outstanding as of March 31, 2025. About Cadrenal Therapeutics, Inc. Cadrenal Therapeutics, Inc. is a biopharmaceutical company developing therapeutics for patients with cardiovascular disease. Cadrenal's lead investigational product is tecarfarin, a novel oral vitamin K antagonist anticoagulant that addresses unmet needs in anticoagulation therapy. Tecarfarin is a reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation. Although warfarin is widely used off-label for a number of indications, extensive clinical and real-world data have shown it can have significant, serious side effects. With tecarfarin, Cadrenal is advancing an innovative solution to address the unmet needs in anticoagulation therapy, aiming to reduce the clinical complexities of warfarin and capture value in a market with high demand for safer, more manageable treatment options. Cadrenal is pursuing a pipeline-in-a-product approach with tecarfarin. Tecarfarin received Orphan Drug designation (ODD) for advanced heart failure patients with implanted mechanical circulatory support devices, including Left Ventricular Assisted Devices (LVADs). The Company also received ODD and fast-track status for tecarfarin in end-stage kidney disease and atrial fibrillation (ESKD+AFib). Cadrenal is opportunistically pursuing business development initiatives with a longer-term focus on creating a pipeline of cardiovascular therapeutics. For more information, visit and connect with us on LinkedIn. Safe Harbor Any statements in this press release about future expectations, plans, and prospects, as well as any other statements regarding matters that are not historical facts, may constitute 'forward-looking statements.' The words 'anticipate,' 'believe,' 'continue,' 'could,' 'estimate,' 'expect,' 'intend,' 'may,' 'plan,' 'potentially,' 'predict,' 'project,' 'should,' 'target,' 'will,' 'would' and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These statements include statements regarding the appointment of James Ferguson, M.D., FACC, FAHA, as the Company's Chief Medical Officer positioning the Company for success in reviewing potential assets to add to its portfolio and designing and executing its clinical program for tecarfarin; the finalized Collaboration Agreement with Abbott validating the critical need in the market for a new anticoagulant for patients with left ventricular assist devices (LVADs); Abbott sharing insights from recent HeartMate 3™ clinical trials and supporting Cadrenal with trial design, site identification, trial awareness, and HeartMate 3™ expertise; the LVAD market projected to nearly double by 2032; and tecarfarin having the potential to provide clinical benefit in additional high-need cardiovascular, renal, and mechanical heart valve indications, reinforcing tecarfarin's potential value proposition for patients. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including the ability to utilize Abbott's expertise to advance tecarfarin, the ability to successfully collaborate with Abbott, the initiation of the pivotal clinical trial for tecarfarin in LVAD patients by Cadrenal; for tecarfarin to provide clinical benefit in additional high-need cardiovascular, renal, and mechanical heart valve indications, reinforcing tecarfarin's potential value proposition for patients; the ability of Cadrenal to build a pipeline of specialized cardiovascular therapeutics and other assets and the other risk factors described in the Company's Annual Report on Form 10-K for the year ended December 31, 2024, and the Company's subsequent filings with the Securities and Exchange Commission, including subsequent periodic reports on Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. Any forward-looking statements contained in this press release speak only as of the date hereof and, except as required by federal securities laws, the Company specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events, or otherwise. (Tables to Follow) Cadrenal Therapeutics, Inc. Balance Sheets March 31, 2025 (unaudited) Assets: Current assets: Cash and cash equivalents $ 7,336,072 $ 10,017,942 Interest receivable 24,664 38,153 Prepaid expenses and other current assets 575,605 42,257 Deferred offering costs 8,451 14,445 Total current assets 7,944,792 10,112,797 Property, plant and equipment, net 4,678 6,944 Other assets 3,792 3,792 Total assets $ 7,953,262 $ 10,123,533 Liabilities and Stockholders' Equity: Current liabilities: Accounts payable $ 1,278,402 $ 1,502,468 Accrued liabilities 561,764 1,181,490 Total current liabilities 1,840,166 2,683,958 Total liabilities 1,840,166 2,683,958 Stockholders' equity: Preferred stock, $0.001 par value, 7,500,000 shares authorized, no shares issued and outstanding at March 31, 2025 and December 31, 2024 - - Common stock, $0.001 par value; 75,000,000 shares authorized, 1,909,732 shares issued and outstanding as of March 31, 2025; 1,782,486 shares issued and outstanding as of December 31, 2024 1,909 1,782 Additional paid-in capital 35,679,350 33,160,576 Accumulated deficit (29,568,163 ) (25,722,783 ) Total stockholders' equity 6,113,096 7,439,575 Total liabilities and stockholders' equity $ 7,953,262 $ 10,123,533 Expand (1) All share and per share information has been retroactively adjusted to reflect the 1-for-15 reverse stock split effected on August 20, 2024. Expand
